Highlight
Depemokimab, an ultra-long-acting anti-IL-5 biologic designed for twice-yearly dosing, was tested as a switch strategy in patients with severe asthma already doing well on mepolizumab or benralizumab.
In NIMBLE, annualized clinically significant exacerbation rates were low in both groups, but the prespecified noninferiority criterion was not met: rate ratio 1.16, 95% confidence interval 0.98 to 1.38, with the upper bound exceeding the noninferiority margin of 1.28.
Despite this statistical result, most participants in both arms had no clinically significant exacerbations over 52 weeks, and asthma control, quality of life, and lung function remained stable.
Adverse events were comparable between depemokimab and continued active comparator therapy, supporting the safety of switching in this selected biologic-responsive population.
Background
Severe asthma remains a high-burden condition despite major advances in type 2 inflammation-directed therapy. For patients with eosinophilic disease, biologics targeting interleukin-5 (IL-5) or the IL-5 receptor have transformed outcomes by reducing exacerbations, sparing oral corticosteroids, and improving symptom control. Mepolizumab and benralizumab are well-established options in this treatment class, but they require repeated administration at four- or eight-week intervals. In practice, dosing frequency can affect patient convenience, treatment adherence, healthcare utilization, and system-level delivery costs.
Depemokimab was developed to address this practical limitation. It is described as the first ultra-long-acting biologic with high IL-5 binding affinity, high potency, and an extended half-life that enables dosing every 26 weeks. If efficacy can be maintained with twice-yearly administration, the drug could represent a meaningful shift in biologic treatment logistics for severe eosinophilic asthma.
However, switching stable patients from an effective biologic to a longer-acting alternative raises an important clinical question. Demonstrating benefit in biologic-naive patients is not enough; clinicians also need evidence on whether patients already controlled on mepolizumab or benralizumab can transition safely without losing protection against exacerbations. The NIMBLE trial was designed to answer precisely this question.
Study Design
NIMBLE was a multicenter, randomized, double-blind, double-dummy, parallel-group, phase 3A noninferiority trial registered as NCT04718389. The study enrolled participants aged 12 years or older with asthma who had documented clinical benefit while receiving mepolizumab 100 mg subcutaneously every four weeks or benralizumab 30 mg subcutaneously every eight weeks for at least 12 months before randomization.
This is an important design feature: the trial did not test whether depemokimab works in uncontrolled severe asthma broadly, but whether it can maintain control after switching from other effective IL-5-pathway biologics in a carefully selected responder population.
Participants were randomized 1:1 to one of two strategies:
Depemokimab switch strategy
Depemokimab 100 mg subcutaneously every 26 weeks, with double-dummy masking to preserve blinding.
Continuation strategy
Maintenance of the participant’s previous biologic, either mepolizumab or benralizumab, according to its standard schedule.
The primary endpoint was the annualized rate of clinically significant exacerbations over 52 weeks. The predefined noninferiority margin for the rate ratio was 1.28. In practical terms, noninferiority would only be declared if the upper bound of the 95% confidence interval for the exacerbation rate ratio remained below 1.28.
Safety endpoints included adverse events, with additional assessment of symptom control, health-related quality of life, and lung function.
Key Findings
Primary efficacy outcome: noninferiority was not formally demonstrated
A total of 848 participants received depemokimab and 839 received active comparator therapy. Over 52 weeks, the annualized rate of clinically significant exacerbations was 0.57 with depemokimab and 0.49 with continued mepolizumab or benralizumab. The rate ratio was 1.16, with a 95% confidence interval of 0.98 to 1.38.
This is the central result of the study. Although the point estimate suggests only a modest numerical increase in exacerbation rate after switching, the upper confidence limit of 1.38 exceeded the prespecified noninferiority margin of 1.28. Therefore, by the trial’s statistical framework, noninferiority was not met.
This distinction matters. The trial did not show superiority, and it also did not achieve its formal criterion for saying the switch was statistically no worse than remaining on prior therapy. That said, the confidence interval crossed 1.0 and included the possibility of near-equivalent outcomes. The result is best interpreted as inconclusive with respect to noninferiority, rather than proof of clinically important inferiority.
Low event rates in both groups complicate interpretation
The absolute exacerbation rates were low in both treatment arms. Most participants experienced no clinically significant exacerbations during the 52-week study period. This reflects the fact that the study population consisted of patients already benefiting from targeted biologic therapy before enrollment. In such a population, event rates are compressed, making it harder for a noninferiority trial to generate a narrow confidence interval.
From a clinical perspective, the low baseline risk is reassuring. From a methodological perspective, it means the study may have been challenged by limited separation and by the statistical difficulty of proving noninferiority when both strategies perform well and the event count is relatively sparse.
Secondary clinical outcomes remained stable
Health-related quality of life, asthma control, and lung function outcomes were reported as stable throughout the trial in both groups. Although the abstract does not provide detailed numerical results for these measures, the direction of effect is important. Patients who switched to depemokimab did not appear to experience broad deterioration in day-to-day disease status, even though the primary noninferiority endpoint was not met.
For clinicians, this is highly relevant. Exacerbations are the most important hard clinical endpoint in severe asthma trials, but symptom burden, activity limitation, rescue medication use, and lung function are what patients experience every day. Stability across these domains supports the idea that a substantial proportion of stable patients can likely switch without obvious clinical destabilization over one year.
Safety profile was comparable
Adverse events were comparable between depemokimab and active comparator therapy. No major new safety signal is highlighted in the abstract. This is consistent with the broader experience that IL-5-pathway biologics generally have favorable tolerability profiles.
The safety finding is especially relevant in a switch trial. A new agent with less frequent dosing would lose much of its appeal if it introduced additional toxicity, immunogenicity, or delayed adverse effects. NIMBLE provides reassurance that, at least over 52 weeks, switching did not meaningfully alter the overall safety profile compared with continued treatment on established anti-IL-5 or anti-IL-5 receptor therapy.
Clinical Interpretation
NIMBLE is best understood as a pragmatic maintenance-switch study rather than a de novo efficacy study. Its message is nuanced.
On one hand, the study missed its prespecified noninferiority objective. For evidence-based clinicians and payers, this means the trial did not deliver the strict statistical confirmation that twice-yearly depemokimab preserves exacerbation protection to within the chosen margin relative to continued mepolizumab or benralizumab. That result should not be minimized.
On the other hand, the totality of the data is more reassuring than the primary endpoint alone may suggest. Exacerbation rates were low, most participants remained exacerbation-free, patient-reported outcomes and lung function were stable, and safety was similar. Therefore, the findings do support the practical conclusion stated by the authors: selected patients already controlled on mepolizumab or benralizumab may be able to switch safely to depemokimab.
The key word is selected. This population had documented prior response to IL-5 pathway inhibition and had already achieved disease stability. NIMBLE does not establish that all patients with severe eosinophilic asthma should be switched routinely, nor does it define which subgroups might be at greater risk for loss of exacerbation control after transition.
Why Might Noninferiority Have Been Missed?
Several explanations are plausible.
First, the study population had low residual exacerbation risk because participants were already effectively treated. In such settings, even small random differences can widen confidence intervals.
Second, switching within the same mechanistic pathway is biologically rational, but mepolizumab, benralizumab, and depemokimab are not identical. Mepolizumab and depemokimab neutralize IL-5 directly, whereas benralizumab targets the IL-5 receptor alpha and induces eosinophil depletion through antibody-dependent cell-mediated cytotoxicity. Subtle mechanistic differences may matter in some patients, especially those with highly eosinophil-driven exacerbation phenotypes.
Third, the chosen noninferiority margin of 1.28 is clinically and statistically consequential. Noninferiority trials depend heavily on margin selection; a modestly different margin or a larger sample with more events could have altered the conclusion.
Fourth, dosing interval extension itself may not be neutral for every patient. Even with prolonged half-life, less frequent administration could theoretically permit breakthrough biology in a subset of individuals toward the end of the dosing interval. Whether this contributed meaningfully in NIMBLE is uncertain from the abstract alone.
Implications for Practice
For clinicians treating severe asthma, NIMBLE offers a useful but not definitive answer.
Twice-yearly dosing is highly attractive. It could reduce treatment burden, improve patient satisfaction, lessen logistical barriers for those with limited access to specialty care, and simplify biologic delivery programs. For adolescents and working-age adults, fewer injections may translate into better persistence with therapy and less disruption to daily life.
Yet switching a stable patient is always a risk-benefit decision. The NIMBLE data suggest that many patients can switch without obvious clinical deterioration, but the statistical failure to show noninferiority means clinicians should not assume interchangeable maintenance efficacy at the population level.
A reasonable approach would be individualized decision-making. Patients most likely to value and potentially benefit from twice-yearly treatment include those with adherence challenges, substantial travel distance to care centers, injection fatigue, or strong preference for lower treatment frequency. Conversely, patients with a recent history of frequent or severe exacerbations despite prior control, or those whose disease course has been difficult to stabilize, may warrant greater caution until more subgroup data are available.
Careful follow-up after switching would also be prudent. Monitoring should include exacerbation frequency, symptom control, rescue inhaler use, oral corticosteroid bursts, and objective markers such as spirometry when available. If disease instability emerges, a low threshold for reassessment of biologic strategy is appropriate.
Strengths and Limitations
Strengths
The trial has several important strengths. It was randomized, double-blind, and double-dummy, reducing bias in a switch setting where treatment schedules differ. The multicenter international design improves external validity. The active-comparator framework is clinically meaningful because it mirrors a common real-world question: continue a working biologic or change to one with a more convenient schedule.
The study also addressed an underexplored area. Switch trials in severe asthma are far less common than placebo-controlled registration studies, despite the fact that real-world severe asthma care often involves treatment transitions rather than first-line biologic initiation.
Limitations
The biggest limitation is inherent to the studied population: participants were already responsive and stable on biologic therapy. Results therefore may not generalize to uncontrolled patients, biologic nonresponders, oral corticosteroid-dependent subgroups, or patients switching for lack of efficacy.
The abstract provides limited granular detail on subgroup analyses, biomarker trajectories, and the magnitude of changes in patient-reported outcomes and lung function. These data will be important for identifying whether outcomes differed according to prior biologic type, age, baseline eosinophil status, or exacerbation history.
Another limitation is interpretive tension between statistical and clinical conclusions. While the authors reasonably note that switching may be safe, some readers may feel that the wording should remain closely anchored to the missed noninferiority endpoint. Safety and maintenance of average disease control do not fully substitute for failure to meet the primary efficacy criterion.
Expert Commentary
NIMBLE sits within a broader shift in severe asthma management: moving from simply proving biologic efficacy toward optimizing long-term treatment strategy, convenience, and patient-centered care. Current severe asthma guidance, including the Global Initiative for Asthma, emphasizes phenotype-directed biologic selection, regular reassessment of response, and shared decision-making. NIMBLE adds useful evidence to that framework by showing that treatment convenience can be studied rigorously, not just assumed to be beneficial.
Biologically, depemokimab’s promise is clear. Long-duration IL-5 neutralization is a logical extension of the eosinophil-targeted treatment paradigm. The unresolved issue is whether convenience can be achieved without even small losses in exacerbation protection among patients already benefiting from other IL-5-axis agents. NIMBLE suggests the answer may be yes for many patients, but not with enough precision to satisfy a formal noninferiority threshold.
This is exactly the type of result that should encourage deeper investigation rather than simplistic interpretation. Further analyses of eosinophil suppression over the dosing interval, subgroup outcomes by prior biologic, and real-world adherence and patient preference will be especially informative.
Conclusion
The NIMBLE trial provides the first randomized controlled evidence on switching patients with severe asthma from mepolizumab or benralizumab to twice-yearly depemokimab. The trial did not meet its prespecified noninferiority endpoint for clinically significant exacerbations over 52 weeks, with a rate ratio of 1.16 and a 95% confidence interval extending beyond the noninferiority margin.
Even so, the overall clinical picture was reassuring: exacerbation rates were low in both groups, most participants remained exacerbation-free, asthma control and lung function were maintained, and safety was comparable. These findings suggest that for selected patients already stable on IL-5-pathway biologics, switching to twice-yearly depemokimab may be a feasible and safe option, especially when reduced treatment burden is a major goal.
The study should influence practice with nuance. It supports informed, individualized switching decisions rather than broad assumptions of therapeutic equivalence. As longer-term and subgroup data emerge, clinicians will be better positioned to identify which patients can gain the most from ultra-long-acting eosinophil-targeted therapy without compromising disease control.
Funding and ClinicalTrials.gov
ClinicalTrials.gov identifier: NCT04718389.
The abstract provided does not specify funding details. Readers should consult the full published article for sponsor and funding disclosures.
References
Chupp G, Nagase H, Skowasch D, Devouassoux G, Côté A, Jackson DJ, Jackson DJ, Wechsler ME, Imber V, McGinniss JE, O K S, Howarth P, Pavord ID; NIMBLE Study Investigators. Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE). American Journal of Respiratory and Critical Care Medicine. 2026 May 1;212(5):921-935. PMID: 41738176.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024 update. Available from: https://ginasthma.org
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma. New England Journal of Medicine. 2012;367(13):1198-1207.
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists: a randomized, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-2127.